927 Shares in Danaher Co. (NYSE:DHR) Acquired by Allen Capital Group LLC

Allen Capital Group LLC acquired a new position in Danaher Co. (NYSE:DHR) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 927 shares of the conglomerate’s stock, valued at approximately $214,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. DHJJ Financial Advisors Ltd. purchased a new position in shares of Danaher in the third quarter worth approximately $25,000. BKM Wealth Management LLC purchased a new position in Danaher during the fourth quarter valued at approximately $27,000. OFI Invest Asset Management purchased a new position in Danaher during the third quarter valued at approximately $30,000. First Capital Advisors Group LLC. purchased a new position in Danaher during the second quarter valued at approximately $32,000. Finally, BOK Financial Private Wealth Inc. purchased a new position in Danaher during the third quarter valued at approximately $34,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on DHR. Royal Bank of Canada lifted their price target on shares of Danaher from $254.00 to $282.00 and gave the company an “outperform” rating in a report on Wednesday, January 31st. KeyCorp lifted their price objective on shares of Danaher from $260.00 to $290.00 and gave the company an “overweight” rating in a research report on Thursday, February 1st. JPMorgan Chase & Co. lifted their price objective on shares of Danaher from $250.00 to $270.00 and gave the company an “overweight” rating in a research report on Wednesday, December 20th. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. Finally, Citigroup lifted their price objective on shares of Danaher from $255.00 to $280.00 and gave the company a “buy” rating in a research report on Wednesday, January 31st. Seven analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $267.43.

Insiders Place Their Bets

In other news, SVP Georgeann Couchara sold 2,622 shares of the business’s stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total transaction of $636,280.74. Following the completion of the sale, the senior vice president now directly owns 4,244 shares of the company’s stock, valued at $1,029,891.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Teri List sold 3,289 shares of the business’s stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $248.32, for a total transaction of $816,724.48. Following the completion of the sale, the director now directly owns 19,726 shares of the company’s stock, valued at $4,898,360.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Georgeann Couchara sold 2,622 shares of the business’s stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total transaction of $636,280.74. Following the sale, the senior vice president now directly owns 4,244 shares of the company’s stock, valued at $1,029,891.48. The disclosure for this sale can be found here. Insiders sold 32,957 shares of company stock valued at $8,265,802 over the last three months. 10.90% of the stock is owned by company insiders.

Danaher Stock Up 0.3 %

NYSE DHR opened at $240.34 on Wednesday. The company has a quick ratio of 1.37, a current ratio of 1.68 and a debt-to-equity ratio of 0.31. The company has a fifty day moving average of $249.42 and a two-hundred day moving average of $229.79. The firm has a market capitalization of $177.98 billion, a price-to-earnings ratio of 37.61, a PEG ratio of 3.64 and a beta of 0.83. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $259.00.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, January 30th. The conglomerate reported $2.09 EPS for the quarter, topping the consensus estimate of $1.91 by $0.18. The company had revenue of $6.41 billion during the quarter, compared to analyst estimates of $6.10 billion. Danaher had a net margin of 17.26% and a return on equity of 12.25%. Danaher’s quarterly revenue was down 10.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.87 earnings per share. On average, analysts predict that Danaher Co. will post 7.62 earnings per share for the current year.

Danaher Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 26th. Shareholders of record on Thursday, March 28th will be paid a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.45%. This is a positive change from Danaher’s previous quarterly dividend of $0.24. The ex-dividend date of this dividend is Wednesday, March 27th. Danaher’s payout ratio is presently 16.90%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.